Command Palette

Search for a command to run...

SOLARA

594.85-1.06%
Market Cap
₹2,893.03 Cr
Stock P/E
117.99
ROCE
6.07%
ROE
0.05%
Book Value
₹230.38

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
  • Q1 FY26 revenue momentum with margin strength: QoQ revenue rose ~15% to INR 320 crores and margins stayed healthy (54% GM with INR173 crores gross profit), underpinning EBITDA growth.
  • Strategic pivot to growth with margin expansion and governance improvements, supported by strong contribution from developed markets (77% of sales).
NEGATIVES
  • Industry pricing pressure in the generic API space, particularly ibuprofen, driving the shift toward higher-margin derivatives.
  • CRAMS requires substantial capex and time to scale, with initial investment of around INR200 crores and potentially INR400-500 crores, taking 3-4 years to become meaningful.

Peers Summary

Sector Leader

Solara Active Pharma Sciences Ltd. is underperforming compared to its peers across key financial metrics, particularly in revenue growth and profitability. Companies like Sun Pharmaceutical and Cipla showcase strong growth and efficiency, making them sector leaders, while Solara's high PE ratio and negative profitability margins indicate overvaluation and financial stress.

Key Points
  • Solara has the lowest revenue growth YoY and 3-Year among peers.
  • Sun Pharma leads in profitability with the highest ROE and PAT margin.
  • Solara has a significantly high PE ratio of 140.35, indicating it may be overvalued.
  • Cipla and Dr. Reddy’s are attractive due to their low PE ratios and strong returns.
Top Performers
Sun Pharmaceutical Industries Ltd.

Highest revenue growth and profitability metrics in the sector.

Cipla Ltd.

Strong growth with a low PE ratio and high ROE.

Mankind Pharma Ltd.

Excellent revenue growth and profitability, coupled with a low debt ratio.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.